• More Shraddha Ashok
• Dama Ganesh Yogiraj
• Joshi Sumit Ashok
• Gaikwad Asmita Vikas

Parkinson’s disease (PD) is a neurodegenerative brain disorder with a constellation of motor abnormalities, such as bradykinesia, resting tremor, cogwheel rigidity, and postural instability, as well as neuropsychiatric symptoms including depression, dementia, apathy, hallucinations, and delusions.1–7 In 2013, approximately 53 million people worldwide were affected by PD, and there were approximately 103,000 PD-related deaths.8 In patients with PD, neurons die, leading to a lack of the available dopamine in the brain responsible for transmitting signals between areas of the brain used for coordination of smooth and balanced muscle movement. Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the pathophysiological loss or degeneration of dopaminergic neurons in the substantia nigra and the presence of neuronal Lewy bodies. The recently developed orally active a-aminoamide derivative safinamide has both dopaminergic and non-dopaminergic (glutamatergic) properties. Safinamide is the first new chemical entity to be approved for the treatment of PD in the last decade.

Parkinson’s disease (PD), Safinamide, monoamine oxidase-B inhibitor, Pharmacodynamics, Clinical Efficacy.

"BRIEF OVERVIEW OF PARKINSON’S DISEASE TREAT BY SAFINAMIDE", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.11, Issue 6, page no.i393-i406, June-2024, Available :http://www.jetir.org/papers/JETIR2406841.pdf

"BRIEF OVERVIEW OF PARKINSON’S DISEASE TREAT BY SAFINAMIDE", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.11, Issue 6, page no. ppi393-i406, June-2024, Available at : http://www.jetir.org/papers/JETIR2406841.pdf